Online Inquiry
Intracerebral hemorrhage (ICH) involves bleeding directly within the brain tissue, and its severity is dictated by both the extent and location of the hemorrhage. ICH is associated with notably high morbidity and mortality rates. The primary causes of ICH include hypertension, arteriovenous malformations, and head trauma. Treatment strategies are predominantly aimed at halting the bleeding, evacuating the blood clot (hematoma), and alleviating intracranial pressure. Extensive preclinical research is essential for understanding the pathogenesis of hemorrhagic stroke and for developing potential treatments to mitigate its effects.
Fig. 1 Cerebrovascular causes of ICH. (Magid-Bernstein, et al., 2022)
With years of expertise in stroke research, we possess a profound understanding of preclinical testing methods for ICH therapies. Ace Therapeutics can accelerate your preclinical ICH research initiatives by offering specialized study design consulting, well-characterized animal models, and a wide range of assays.
Ace Therapeutics offers several animal models of ICH to help clients investigate the pathophysiology of ICH and develop new therapeutics. We can select suitable models to meet the specific needs and objectives of our clients' projects.
We build ICH model by injecting different doses of bacterial collagenase (ranging from 0.01 to 0.1 units in 0.5 to 2 mL) into the rat striatum or mouse basal ganglia region. These models allow us to help clients:
We use an infusion system to collect autologous blood from the tail vein of a rat or mouse and inject it into the striatum. This model allows us to assist clients in:
We can assist clients in constructing an ICH model by introducing micro-balloons into rats to investigate the mass effects of ICH. Additionally, we can validate this model through the examination of brain histology, intracranial pressure (ICP), and cerebral blood flow.
This model is similar to the autologous blood injection model with the difference of injecting only thrombin into the brain of animal. We use this model to help clients study the effects of thrombin in ICH.
With our extensive experience and expertise in drug discovery, Ace Therapeutics is committed to helping our clients develop novel therapies for ICH.
We provide comprehensive services to help our clients evaluate the efficacy of drugs for intracerebral hemorrhage.
| Preclinical Evaluation Services | Service Details |
|---|---|
| Hematoma/lesion volume measurement | Assess changes in hematoma volume in animal models of ICH before and after drug administration by morphological measurements. Analyze hematoma volume and other critical parameters, including glucose metabolism, using advanced imaging techniques such as magnetic resonance imaging (MRI) and hybrid positron emission tomography/computed tomography (PET/CT). |
| Brain edema measurement | Quantify brain edema or brain water content in animal models of ICH before and after drug administration by using a gravimetric method and MRI. |
| BBB disruption assessment | Assess BBB permeability in ICH animal models and screen for drugs that attenuate BBB disruption and neurological deficits. |
| Histological evaluation | Provide histological staining with hematoxylin and eosin to evaluate brain lesions in animal models of ICH. |
Ace Therapeutics offers customized preclinical ICH research services. With our cutting-edge technology and a team of experts, we enhance the understanding of the complexities associated with ICH and propel the development of innovative therapeutics. Contact us today to begin your journey of discovery.
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.